PFIZER LTD.

Pfizer Ltd has announced the closure of its trading window for the purpose of declaring its unaudited financial results for the quarter ending June 30, 2026. The window will be closed from Tuesday, June 30, 2026, effective from the close of business. It will reopen 48 hours after the financial results are officially made public. This measure is a standard corporate governance practice to prevent insider trading during the sensitive period of financial result announcement.

Pfizer Ltd has appointed M/s. Kishore Bhatia & Associates as its Cost Auditors for the financial year ending March 31, 2027. The appointment was made by the Board of Directors on May 12, 2026, following the recommendation of the Audit Committee. The remuneration for the auditors will be presented to the shareholders for ratification at the upcoming Annual General Meeting. M/s. Kishore Bhatia & Associates is a Mumbai-based firm of Practicing Cost Accountants offering services such as cost audits, certifications, and consultancy across various industries.

The Board of Directors of Pfizer Ltd approved the convening of the 75th Annual General Meeting (AGM) of the company on July 28, 2026. The meeting will be held via Video-Conferencing (VC) / Other Audio-Visual Means (OAVM) in accordance with the circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India.

Pfizer Ltd has fixed Friday, July 17, 2026, as the record date to determine members' entitlement to the final dividend for the financial year ended March 31, 2026. This follows the Board of Directors' recommendation on May 12, 2026, of a final dividend of ₹75 per equity share of ₹10 each (750%) for the same financial year.

The Board of Directors of Pfizer Ltd has recommended a final dividend of ₹75 per equity share of ₹10 each (750%) for the financial year ended March 31, 2026. The record date for determining entitlement to the dividend is fixed as Friday, July 17, 2026.

Pfizer Ltd's Board of Directors, in a meeting held on May 12, 2026, approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹75 per equity share (750%) of ₹10 each. The dividend, if declared at the AGM, will be paid on or after August 4, 2026, to shareholders on the register as of the record date, July 17, 2026. The 75th Annual General Meeting will be held on July 28, 2026, via video conferencing. M/s. Kishore Bhatia & Associates were appointed as Cost Auditors for the financial year ending March 31, 2027.

Pfizer Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹75 per equity share. The dividend, if declared at the AGM, will be paid on or after August 4, 2026, to shareholders on record as of July 17, 2026. The 75th Annual General Meeting will be held on July 28, 2026, via video conferencing. M/s. Kishore Bhatia & Associates were appointed as Cost Auditors for the financial year ending March 31, 2027.

Pfizer Ltd has announced a Board of Directors meeting scheduled for May 12, 2026, to consider and approve the financial results for the quarter and year ended March 31, 2026. The board will also consider recommending a dividend, if any, for the financial year ended March 31, 2026. The trading window for dealing in the company's shares has been closed from March 31, 2026, until 48 hours after the financial results are made public.

Pfizer Ltd has received an Assessment Order from the Income Tax Department for a tax demand of ₹85,73,96,440 related to the financial year 2022-23. The order follows a scrutiny of returns and includes a show cause notice for initiating penalty proceedings. Pfizer is evaluating the order and plans to take appropriate steps, including filing an appeal. The company believes it has strong grounds on merits and does not expect the order to have a material impact on its financial position or operations.

Pfizer Ltd has announced changes in its senior management. Mr. Deepak Rakheja, Strategic Partnerships, Channel Development and International Neighbouring Markets Lead, has resigned effective July 8, 2026, to pursue opportunities outside Pfizer Limited. Mr. Anil Pattanshetty, Senior Director, Business Operations, will transition to another Pfizer Group Company effective April 1, 2026, and will cease to be a Senior Management Personnel of the Company effective March 31, 2026. Both individuals have submitted their resignation letters as required by the SEBI Listing Regulations 2015.